FDA
-
-
-
-
-
-
-
Calidi Biotherapeutics Announces Participation in RedChip’s April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms
-
-
-
-
-
-
-
Calidi Biotherapeutics announces proposed public stock offering
-
-
-
-
-
-
-
Calidi Biotherapeutics Receives FDA Fast Track Designation for CLD-201 (SuperNova), a First-In-Class Stem-Cell Loaded Viral Therapy for the Treatment of Patients with Soft Tissue Sarcoma
-
-
-
-
-
-
-
Calidi Biotherapeutics (CLDI) Announces Proposed Public Offering
-
-
-
-
-
-
-
Calidi to Effect Reverse Stock Split
-
-
-
-
-
-
-
Calidi Biotherapeutics (CLDI) Exercises $2.1M of Warrants
-
-
-
-
-
-
-
Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public Offering
-
324,764 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

